Tute Genomics

Los Angeles, United States Founded: 2012 • Age: 14 yrs Acquired By PierianDx
Cloud-based genome analysis for precision medicine is provided.
Annual revenue - Latest available
Total funding $7.4M 4 rounds
Employees - Tracked headcount
Investors 7 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Tute Genomics

Tute Genomics is a company based in Los Angeles (United States) founded in 2012 was acquired by PierianDx in October 2016. Tute Genomics has raised $7.39 million across 4 funding rounds from investors including Tencent, Intermountain Healthcare and Wellfound. Tute Genomics has completed 1 acquisition, including Knome. Tute Genomics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.

  • Headquarter Los Angeles, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $7.39 M (USD)

    in 4 rounds

  • Latest Funding Round
    $868.53 K (USD), Series A

    Oct 27, 2015

  • Investors
    Tencent

    & 6 more

  • Employee Count
    Not available
  • Investments & Acquisitions
  • Acquired by
    PierianDx

    (Oct 11, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Tute Genomics

Tute Genomics has successfully raised a total of $7.39M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $868.53 thousand completed in October 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Tute Genomics

Tute Genomics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Tencent, Intermountain Healthcare and Wellfound.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early-stage tech investments are directed by Eurovestech across multiple sectors.
Locked Locked Locked
Healthcare startups are accelerated via a five-day program by Healthbox.
Locked Locked Locked
Investments are directed toward early-stage tech startups by Album VC.
Locked Locked Locked
Premium access

Investor details for Tute Genomics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Tute Genomics

Tute Genomics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Knome.

Investments
Premium access

Investment portfolio details for Tute Genomics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Human genome interpretation software and services are provided.
Locked Locked 2007 Locked
Premium access

Complete acquisition details for Tute Genomics

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Tute Genomics

Premium access

Detailed financials for Tute Genomics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Tute Genomics Comparisons

Tute Genomics Primary company
Description
Cloud-based genome analysis for precision medicine is provid...
Location
Los Angeles, United States
Founded Year
2012
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Tute Genomics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Tute Genomics

Tute Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
Locked Locked Locked
MicroRNA-based therapeutics are developed for treating multiple diseases.
Locked Locked Locked
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
Locked Locked Locked
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
Locked Locked Locked
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
Locked Locked Locked
Therapeutics for aging diseases are developed by targeting senescent cells.
Premium access

Detailed competitors of Tute Genomics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Tute Genomics

Premium access

Complete news archive for Tute Genomics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tute Genomics

Tute Genomics was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Tute Genomics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.

Tute Genomics is a funded company, having raised a total of $7.39M across 4 funding rounds to date.

Tute Genomics offers clinical-grade web-based application, powered by machine learning algorithms that allow researchers and clinicians to analyze, utilize, and interpret human genomes data for scientific discovery and individualized treatment. The companys platform also supports disease gene finding and biomarker discovery, as well as provides machine intelligence, genome management, data filtration for streamlined output, and association analysis. Its platform serves pharmaceuticals and biotechnology companies, genetics laboratories, and research centers.

Tute Genomics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.

Tute Genomics has made 1 acquisition, including Knome.

Tute Genomics has 7 investors. Key investors include Tencent, Intermountain Healthcare, Wellfound, PierianDx, and Eurovestech.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available